Using flow cytometry and high-throughput confocal imaging approaches, we tested ZL-1201 in combination with trastuzumab in HER2-amplified solid tumor models including HCC1954, SKOV3, BT-474, HCC2218, AU565 (Fig. 2A; Supplementary Fig. S2F), cetuximab in EGFR-expressing head and neck squamous cell carcinoma (HNSCC) and colorectal cancer models including FaDu, Cal27, NCI.H747, and SW48 (Fig. 2B; Supplementary Fig. S2G; Supplementary Fig. S3F), and rituximab in the CD20-expressing Toledo lymphoma cell (Fig. 2C; Supplementary Fig. S3G). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.